abrdn plc decreased its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 379,612 shares of the company’s stock after selling 7,471 shares during the period. abrdn plc owned about 0.20% of Cencora worth $85,341,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in COR. Concord Wealth Partners purchased a new stake in Cencora in the third quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Cencora in the 3rd quarter worth about $41,000. Modus Advisors LLC bought a new position in shares of Cencora in the 4th quarter worth about $54,000. Finally, Carolina Wealth Advisors LLC lifted its position in Cencora by 366.7% during the 3rd quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after acquiring an additional 209 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Analysts Set New Price Targets
COR has been the subject of a number of analyst reports. Wells Fargo & Company raised their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Evercore ISI raised their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Barclays raised their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $278.40.
Insider Transactions at Cencora
In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 over the last three months. 10.80% of the stock is currently owned by company insiders.
Cencora Price Performance
Shares of NYSE:COR opened at $251.31 on Wednesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $48.57 billion, a price-to-earnings ratio of 33.46, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The business has a 50-day simple moving average of $239.00 and a two-hundred day simple moving average of $236.39. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $261.25.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- Stock Dividend Cuts Happen Are You Ready?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What is a support level?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.